Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) has announced plans to release its fourth quarter and year-end 2025 financial results on February 25, 2026. Following this announcement, the company will host a conference call at 4:30 p.m. ET (1:30 p.m. PT) to discuss the financial outcomes and highlight recent corporate developments. Investors can participate by dialing +1 833 470 1428 for U.S. callers or +1 646 844 6383 for international participants, using access code 047642. Alternatively, the call will be available via webcast through the Investors section on Mirum's corporate website, with a replay option for those unable to attend live.

Mirum Pharmaceuticals specializes in the rare disease sector, offering a robust portfolio of approved therapies and a promising pipeline of investigational products. The company is dedicated to advancing treatments for underrepresented conditions, leveraging extensive expertise in rare diseases while fostering strong connections to patient communities. Their therapeutic offerings include LIVMARLI® (maralixibat), designed for treating Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), CHOLBAM® (cholic acid) for bile-acid synthesis disorders, and CTEXLI® (chenodiol) for cerebrotendinous xanthomatosis (CTX).

In its clinical pipeline, Mirum is advancing innovative treatments such as volixibat, an IBAT inhibitor, for conditions like primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), alongside brelovitug, a monoclonal antibody targeting chronic hepatitis delta virus (HDV), and MRM-3379, a PDE4D inhibitor for Fragile X syndrome (FXS). Mirum’s commitment to delivering impactful therapies stems from a disciplined approach to development and collaboration within the rare disease ecosystem. For more information, visit their website or follow them on social media platforms.

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) is poised for significant investor attention as it prepares to announce its fourth quarter and year-end financial results for 2025 on February 25, 2026. Analysts and investors alike should closely monitor this announcement, as it will provide critical insights into the company's financial health and progress in addressing rare diseases.

Investors should focus on several key areas during the earnings call. First, revenue trends from the company's commercial products—LIVMARLI®, CHOLBAM®, and CTEXLI®—will be telling indicators of market demand and the effectiveness of Mirum's sales strategies. Any growth in the sales pipeline could signal robust demand and an expanding customer base, further justifying MIRM's valuation.

Additionally, updates on Mirum’s clinical-stage pipeline, particularly concerning volixibat for PSC and PBC, and brelovitug for chronic hepatitis delta virus (HDV), will be crucial. Positive trial data or developments towards regulatory approvals can enhance credibility and increase share price momentum. The success in these trials may highlight Mirum's competitive edge in the rare disease landscape.

Moreover, developments in collaborations and partnerships could indicate Mirum’s positioning for future growth. Investor sentiment can be positively influenced by strategic alliances that enhance its market reach and access to innovation.

The market’s reaction will depend heavily on the context provided during the conference call. Investors should listen for guidance regarding revenue expectations for 2026, management’s assessment of the rare disease market, and any strategic shifts or expansions within the pipeline.

Given Mirum’s purposeful approach to rare diseases and a strong portfolio, the upcoming results may not only reaffirm the company’s market position but also present an opportunity for strategic investment in the biopharmaceutical sector. Investors should prepare to evaluate these factors carefully post-announcement.